Zebrafish Model for Biomedical Research
Language: English
Published by Springer Nature, 2023
- Softcover
- New

Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
US$ 476.85
Quantity: 2 available
Add to basketItem description from seller
505 pages. 9.25x6.10x1.02 inches. In Stock.
Seller Inventory # x-9811652198
- Title
- Zebrafish Model for Biomedical Research
- Author
- Bhandari, Prasan R. (Editor)/ Bharani, Kala Kumar (Editor)/ Khurana, Amit (Editor)
- Publisher
- Springer Nature
- Publication year
- 2023
- Condition
- Brand New
- Binding
- Paperback
- Language
- English
- ISBN 10
- 9811652198
- ISBN 13
- 9789811652196
- Item weight
- 0.7 kilograms
"Synopsis" may belong to another edition of this title.
About the Author
Dr. Prasan R Bhandari is currently serving as professor and head in the department of pharmacology at Symbiosis Medical College for Women at Pune. He has obtained his medical degree from one of the oldest and premier institutes of India i.e. Grant Medical College & J.J.Group of Hospitals, Mumbai. He has received his post-graduation in M.D Pharmacology from the academically renowned institute Topiwala National Medical College, B. Y. L. Nair Charitable Hospital, Mumbai. He has over 25 years of academic, teaching, research, administrative as well as industry experience. He has published several articles in both national and international journals. He has served as an examiner in several universities for both postgraduate and undergraduate medical, dental, physiotherapy and other allied paramedical students.
Prof. Kala Kumar Bharani is currently working as professor and head of the department of veterinary pharmacology and toxicology at the College of VeterinaryScience, Warangal, Telangana. Prof. Bharani graduated from the Andhra Pradesh Agricultural University (APAU), Hyderabad, India and completed his PhD from the Sri Venkateswara Veterinary University (SVVU) Tirupati. He is a recipient of the Telangana State Best Teachers Award, Dr Lalitha Kameswaran Award and Dr S. B. Pandey Award. Currently, he is serving as the secretary-general of the Indian Pharmacological Society (IPS). Prof. Bharani has published more than 50 peer-reviewed research and review articles.
Dr. Amit Khurana is working as a research scientist at the Centre for Biomedical Engineering (CBME), Indian Institute of Technology (IIT) New Delhi, India. Dr. Khurana graduated from the Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), University of Delhi, India. He obtained PhD in pharmacology and toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India. He is a recipient of multiple prestigious fellowships and awards like the DST-DAAD Fellowship, DBT-CNPq Indo-Brazil Fellowship, PC Dandiya Young Scientist Award of the Indian Pharmacological Society (IPS) and Merit Award from the Delhi Pharmacy Council. His research interests include nanomedicine, novel therapeutics for gastroenterological and fibrotic disorders. He has authored more than 40 research and review publications and has contributed to more than 10 book chapters (Elsevier, Springer Nature, CRC Press).
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | US$ 16.93 | US$ 33.87 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Shipping terms
Orders usually dispatched within two working days. Please note that at this time all domestic United Kingdom orders are sent by trackable UPS courier, we choose not to offer a lower cost alternative.